Therapeutic Effect of Quetiapine on Methamphetamine-Induced Psychosis (MAP)

Chulalongkorn University

Status and phase: Completed; Phase 4

Conditions: Methamphetamine-induced Psychosis

Treatments: Dietary Supplement: Vitamin B1-6-12; Drug: Stugeron; Drug: Diazepam

Study type: Interventional

Funder types: Other

Identifiers

NCT01939093

NRCT-53069

Details and patient eligibility

About

The aims of this study are to compare the antipsychotic and adverse events of quetiapine, an atypical antipsychotic drug, to haloperidol, a standard treatment for primary psychotic disorder, in individuals with MAP.

Full description

Eighty individuals with MAP will be randomly assigned into two treatment groups, i.e. treatment with quetiapine and haloperidol. The quetiapine group will receive quetiapine at least 100 mg per day and the haloperidol group will receive haloperidol at least 2 mg per day orally once a day for four weeks. The doses will be increased every 5 days until no psychotic symptom is observed from the Positive and Negative Syndrome Scale. Common antipsychotic adverse events will be checked and documented daily.

Enrollment: 80 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Having a psychotic episode with current use of methamphetamine
• Positive urine toxicology test for methamphetamine on the first day of hospitalization

Exclusion criteria

• Using other illegal substances
• Having a history of primary psychotic disorders or using antipsychotic agents
• Having a chronic medical disease, e.g. essential hypertension, diabetes, epilepsy, stroke

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

80 participants in 2 patient groups

Quetiapine

Experimental group

Description:

Quetiapine 100 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.

Treatment:

Dietary Supplement: Vitamin B1-6-12

Drug: Stugeron

Drug: Diazepam

Haloperidol

Active Comparator group

Description:

Haloperidol 2 mg per day is taken orally once a day for four weeks. The dose is increased every 5 days until no psychotic symptom is observed.

Treatment:

Dietary Supplement: Vitamin B1-6-12

Drug: Stugeron

Drug: Diazepam